HPV vaccine safety: what do the data show?
A research-oriented review of common side effects, serious safety concerns, infertility claims and how post-licensure surveillance has shaped the evidence base.
Reviewed: 22 August 2026
1. What HPV vaccination is intended to prevent
Human papillomavirus infection is associated with cervical cancer and several other cancers, as well as genital warts. HPV vaccination is preventive: it aims to reduce infection with selected HPV types before exposure.
2. Common side effects
The NHS lists pain or swelling at the injection site, headache, high temperature, dizziness, nausea and tiredness among the most common effects. These are generally temporary. Severe allergic reactions can occur, but are described as very rare.
3. Infertility and primary ovarian insufficiency
WHO's safety committee reviewed the infertility concern after case reports and public controversy. Its review considered case reports, passive surveillance and epidemiological studies. WHO concluded that the available data do not support a causal association between HPV vaccination and infertility or primary ovarian insufficiency.
4. Why case reports are not enough
A case occurring after vaccination can identify a hypothesis worth examining, but cannot by itself establish that the vaccine caused the event. Investigators need comparison groups, background rates, timing, biological plausibility and consistency across studies.
5. Autoimmune and neurological concerns
WHO has reviewed concerns including autoimmune conditions and neurological syndromes. Large studies have generally not shown increased rates of the conditions examined among vaccinated populations. Continued surveillance remains important precisely because very rare outcomes may not be visible in pre-licensure trials.
6. Conclusion
The available safety evidence supports a favourable HPV vaccine safety profile, while known reactions such as local pain, fainting/syncope and rare severe allergic reactions are monitored and communicated. Claims of widespread chronic harm have not been supported by the stronger population-level evidence reviewed by WHO.
Source trail
Current UK patient information on dosing, side effects and effectiveness.
GACVS review concluding that available data do not support an association with infertility or primary ovarian insufficiency.
Review of post-licensure evidence and investigated safety concerns.